Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: opicinumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 32 Parkinson's papers of 298 | 0.54 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4180
Sealed predictions
- LINGO1 in dopamine neurons, braak-0.61 (p 0.083) → -0.10 (p 0.802)receipt 4186
Swarm cases
receipt 4186: LINGO1 in dopamine neurons, braak
- power
- full sample -0.38 (p 0.118, n 18), 95% CI -0.72 to +0.10. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.38 (p 0.118, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.61 (p 0.0072, n 18). not the mix.
- skeptic
- leave-one-out range -0.52 to -0.30, sign flips 0; without severely affected donors -0.38 (p 0.118, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LINGO1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts